ClinicalTrials.gg
CompletedNCT01516086Updated Dec 11, 2014

A 12-Week Study in Adult Subjects With Asthma

A Phase 2 interventional study of Fluticasone Propionate (FP) in Asthma, sponsored by Dey. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-12-11.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
30th of 146
498 · median 100
Started
2012
with 12 others
Phase 2
25 of 147
none open now
Registered
87th of 147
by date
Lead sponsor
2 of 147
Dey

Among the 147 studies testing fluticasone in Asthma, this one is the 30th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2012, is one of 25 in phase 2, and was the 87th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This will be a multi-center, randomized, placebo controlled parallel-group study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma. Individual participation will be approximately 16 weeks, including 12 weeks of double-blind treatment.

Read the detailed description

The primary outcome measure is FEV1 (Forced Expiry Volume in 1 second) and the secondary outcome measure is Peak Expiratory Flow Rate (PEFR), Asthma Control Questionnaire (ACQ), Nighttime awakenings and rescue medication usage.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Controlled
  • uncontrolled
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A signed and dated written form prior to the conduct of any study procedures
  2. Males and females between ≥ 18 and ≤ 60 years old.
  3. Non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more than 10 pack-years (e.g., 1 pack [20 cigarettes] per day for 10 years).

6.Ability to understand and comply with the protocol requirements (including completion of daily PEFR, PFT and ACQ), instructions and protocol-stated restrictions.

7.Women of (WOCBP) must have a negative pregnancy test at the screening visit. WOCBP include: any female who has experienced menarche and is not (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP.

WOCBP must agree to avoid becoming pregnant for the duration of the study by using adequate contraception at study entry and throughout the trial. Examples of adequate contraception include the following:

  • Norplant
  • Medroxyprogesterone acetate injection
  • Oral contraception
  • Double-barrier method (e.g., condom and spermicide)
  • Abstinence, with one of the above WOCBP will be advised to notify the Investigator of any changes in their pregnancy status or any change in contraceptive use.

    8.Agreement by subject to abide by the study protocol and its restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Past or present disease, excluding asthma, which as judged by the investigator, may place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives These diseases include, but are not limited to cardiovascular disease, , gastrointestinal disease, hepatic disease, diabetes type I or uncontrolled diabetes, type II, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis, , eosinophilic bronchitis or pulmonary fibrosis).
  2. An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2
  3. A history of to the study drug or its components, including albuterol as rescue medication.
  4. History of illegal drug or alcohol abuse within the past 5 years.
  5. Pregnant or lactating women.
  6. Use of > 8 inhalations per day of SABA on any two consecutive days from screening to randomization (Visits 1 and 2).
  7. Use of an drug or device within 30 days prior to screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
498 participants (actual)

Study arms

  • Experimental
    Fluticasone Propionate (FP) - arm 1

    FP BID (twice daily)

    Drug: Fluticasone Propionate (FP)

  • Experimental
    Fluticasone propionate (FP) - arm 2

    FP BID

    Drug: Fluticasone Propionate (FP)

  • Experimental
    Fluticasone Propionate (FP) - arm 3

    FP BID

    Drug: Fluticasone Propionate (FP)

  • Experimental
    FLuticasone Propionate (FP) - Arm 4

    FP BID

    Drug: Fluticasone Propionate (FP)

  • Experimental
    Fluticasone Propionate (FP) - Arm 5

    FP BID

    Drug: Fluticasone Propionate (FP)

  • Placebo comparator
    Placebo - Arm 6

    Placebo inhalation solution

    Drug: Fluticasone Propionate (FP)

Interventions

06

What researchers measure

Primary outcomes

  1. FEV1 (Forced Expiry Volume in 1 second)

    Time frame: FEV1 at Week 12

Secondary outcomes

  1. Peak Expiratory Flow Rate (PEFR)

    Time frame: PEFR at Week 12

07

Study locations

1 site
  • CU Pharmaceutical Research
    Rock Hill, South Carolina 29732, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 24, 2012
Start
Mar 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Nov 24, 2014
Last update
Dec 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01516086
Lead sponsor
Dey
Responsible party
Sponsor
First posted
Jan 24, 2012
Start date
Mar 2012
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Dec 11, 2014

Study contacts

Imtiaz Chaudry
study director · Dey

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion